On this page

Rezvoglar

insulin glargine-aglr

351(k) Interchangeable Pharmacy-substitutable

Overview

Source: Purple Book

Proprietary name

Rezvoglar

Proper name

insulin glargine-aglr

Licence type

351(k) Interchangeable

BLA number

761215

Applicant

Eli Lilly and Company

Center

CDER

Presentations

First licensure

—

351(k) biosimilar pathway. This product was licensed as highly similar to a reference product, with no clinically meaningful differences in safety, purity or potency. It also carries the interchangeable designation, so a pharmacist may substitute it for the reference product without contacting the prescriber.

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
300UNITS/3ML (100UNITS/ML)	Injection	Subcutaneous	Autoinjector	Rx	December 17, 2021

Reference product

Source: Purple Book

This product is licensed with reference to Lantus (insulin glargine).

View reference product Search the small-molecule catalogue

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity